BCG immunotherapy for superficial bladder cancer

Parmar M , Freedman L , Hargreave T , Tolley D. Prognostic factors for recurrence and follow up policies in the treatment of superficial bladder cancer: report from the British Medical Research Council subgroup on superficial bladder cancer (urological cancer working party). J Urol 1989; 142: 284–8

Pagano F , Garbeglio A , Milani C , Bassi P , and Pegoraro V. Prognosis of bladder cancer. Eur Urol 1987; 13: 145–9

Pearl R. Cancer and Tuberculosis. Am J Hyg 1929; 9: 97–159

Mathé G , Amiel JL , Schwarzenberg L Active immunotherapy for acute lymphoblastic leukaemia. Lancet 1969; i: 697–9

Coe JE , Feldman JD. Extracutaneous delayed hypersensitivity, particularly in guinea pig bladder. Immunology 1966; 10: 127–36

Morales A , Eidinger D , Bruce AW. Intracavitary BCG in the treatment of superficial bladder tumours. J Urol 1976; 116: 180–3

Lamm DL , Thor DE , Harris SC , Reyna JA , Stogdill VD , Rasdwin HM. BCG immunotherapy of superficial bladder cancer. J Urol 1980; 124: 38–40

Bretton PR , Herr HW , Kimmel M The response of patients with superficial bladder cancer to a second course of intravesical BCG. J Urol 1990; 143: 710–13

Catalona WJ , Hudson MA , Gillen DP Risks and benefits of repeated courses of intravesical BCG for superficial bladder cancer. J Urol 1987; 137: 220–4

Ratliff TL , Gillen D , Catalona WJ. Requirement of a thymus dependent immune response for BCG mediated antitumour activity. J Urol 1987; 137: 155–8

Ratliff TL , Kavoussi LR , Catalona WJ. Role of fibronectin in intravesical BCG therapy for superficial bladder cancer. J Urol 1988; 139: 410–14

Beich MJ , Carroll S , Ratliff TL. Internalization of BCG by bladder tumour cells. J Urol 1991; 145: 1316–24

Ratliff TL , Ritchey JK , Yuan JJ , Andrilow GL , Catalona WJ. T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J Urol 1993; 150: 1018–23

Jackson AM , Alexandroff AB , Kelly RW Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after BCG immunotherapy. Clin Exp Immunol 1995; 99: 369–75

Jackson AM , James K. Understanding the most successful immunotherapy for cancer. Immunologist 1994; 2: 208–15

Lattime EC , Gomella LG , McCue PA. Murine bladder carcinoma cells present antigen to BCG specific CD4 T-cells. Cancer Res 1992; 52: 4286–90

Akaza H , Hinotsu S , Aso Y BCG treatment of existing papillary bladder cancer in situ of the bladder. Cancer 1995; 75: 552–9

Harland SJ , Charing CR , Highman W , Parkinson MC , Riddle PR. Outcome in carcinoma in situ of bladder treated with intravesical BCG. Br J Urol 1992; 70: 271–5

Merz VW , Marth D , Kraft R , Ackermann DK , Zingg EJ , Studer UE. Analysis of early failures after intravesical instillation therapy with BCG for carcinoma in situ of the bladder. Br J Urol 1995; 75: 180–4

Lamm DL. Long term results of intravesical therapy for superficial bladder cancer. Urol Clin N Am 1992; 19: 573–80

Lundholm C , Norten BJ , Eckman P A randomized prospective study comparing long term intravesical instillations of MMC and BCG in patients with superficial bladder cancer. J Urol 1996; 156: 372–6

Lamm DL , Crawford ED , Blumenstain B SWOG 8795. A randomized comparison of BCG and MMC prophylaxis in stage Ta & T1 transitional cell carcinoma of the bladder [Abstract]. J Urol 1993; 149: 282A

Rubben H , Graf-Dobberstein C , Ostwald R Prospective randomized study of adjuvant therapy after complete resection of superficial bladder cancer: MMC vs. BCG vs. TUR alone. Immunotherapy of Urological Tumours. Edinburgh: Churchill Livingstone, 1990: 27–36

Vegt PDJ , Witjes A , Witjes WPJ A randomized study of intravesical MMC, BCG-TICE and BCG-RIVM treatment in pTa and pT1 papillary carcinoma and carcinoma in situ of the bladder. J Urol 1995; 153: 929–33

Herr HW , Laudone VP , Badalament RA BCG therapy alters the progression of superficial bladder cancer. J Clin Oncol 1988; 6: 1450–5

Lamm DL , Blumenstein BA , Crawford ED A randomized trial of intravesical doxorubicin and immunotherapy with BCG of transitional cell carcinoma of the bladder. N Engl J Med 1991; 325: 1205–9

Pagano F , Bassi P , Milani C A low dose BCG regimen in superficial bladder cancer: is it effective? J Urol 1991; 146: 32

Herr HW , Schwalb DM , Zhang ZF Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten year follow-up of a prospective randomized trial. J Clin Oncol 1995; 13: 1404–8

Cookson MS , Herr HW , Zhang ZF The treated natural history of high risk superficial bladder cancer: 15 year outcome. J Urol 1997; 158: 62–7

Martinez-Pineiro JA , Jimenez Leon J , Martinez-Pineiro L BCG versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer. J Urol 1990; 143: 502–6

Krege S , Otto T , Rubben H , Meyer R , Gianni G. Final report on a randomized multicentre trial on adjuvant therapy in superficial bladder cancer. TUR only vs. TUR & MMC vs. TUR & BCG. J Urol 1996; 155: 494A (abstract)

Lamm DL , Blumenstein BA , Crissman JD Maintenance bacillus Calmette-Guérin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study. J Urol 2000; 163: 1124–9

Rischmann P , Desgrandchamps F , Lalavaud B , Chopin DK. BCG intravesical instillations: recommendations for side-effects management. Eur Urol 2000; 37: (suppl 1): 33–6

Durek C , Rusch-Gerdes S , Jocham D , Bohle A. Interference of modern antibacterials with Bacillus Calmette-Guérin viability. J Urol 1999; 162: 1959–62

Lamm DL , Steg A , Boccon-Gibod L Complications of bacillus Calmette-Guérin immunotherapy: review of 2602 patients and comparison of chemotherapy complications. EORTC Genitourinary Group Monogr 1989; 6: 335–55